Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.

Thrombosis and haemostasis - 1 Aug 2010

Kao Chung-Yang, Lin Chia-Ni, Yu I-Shing, Tao Mi-Hua, Wu Hua-Lin, Shi Guey-Yueh, Yang Yung-Li, Kao Jau-Tsuen, Lin Shu-Wha

Abstract excerpt

Engineered recombinant factor IX (FIX) with augmented clotting activity may prove useful for replacement therapy, but it has not been studied for risk of thrombosis. We used three mouse models to evaluate thrombosis risk associated with the FIX variant FIX-Triple, which has a 13-fold higher specific activity than wild-type FIX (FIX-WT). Protein infusion of FIX-Triple into haemophilia B mice was not thrombogenic,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chlorides
Share to Coagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Factor IX

Share to Ferric Compounds

Share to Hemophilia B

Share to Hemostasis

Share to Infusions, Intravenous

Source

Identifiers

PMID: 20539913
DOI: 10.1160/TH09-11-0792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.PMID 20539913Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.Semantic proximity Read ↗

Creation of a mouse expressing defective human factor IX.Semantic proximity Read ↗

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.Semantic proximity Read ↗

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodiesSemantic proximity Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.Semantic proximity Read ↗

Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.Semantic proximity Read ↗

Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.Semantic proximity Read ↗

The Function of extravascular coagulation factor IX in haemostasisSemantic proximity Read ↗

Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male miceSemantic proximity Read ↗

FVIIa as used pharmacologically is not TF dependent in hemophilia B miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.